Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, S.; Raz, I.; Bonaca, M.; Mosenzon, Ofri; Toda Kato, Eri; Cahn, A.; G. Silverman, Michael; A. Zelniker, Thomas; Kuder, J.; Murphy, S.; L. Bhatt, Deepak; A Leiter, Lawrence; K Mcguire, Darren; Wilding, J.; Ruff, C.; Gause-Nilsson, I.; Fredriksson, M.; Johansson, P.; Langkilde, A.; Sabatine, M.; S Temelkova-Kurktschiev, Theodora

doi:10.1056/NEJMoa1812389

Public

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Shared by NobleBlocks on Jan 24, 2019 • 12:00 AM UTC

Authors:

S. Wiviott

I. Raz

M. Bonaca

Abstract

BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardi...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!